NOW ENROLLING: CANaspire, Aspa’s investigational gene therapy trial for patients with Canavan disease.
Families can call 1-833-764-2267 (toll-free) or 1-617-861-4617 or email to reach a trial representative.

Aspa Therapeutics, a BridgeBio company, is excited to announce that new data from the CANaspire gene therapy clinical trial were shared in a recent press release. Decreases in N-acetylaspartate (NAA), a chemical marker in Canavan Disease, in the urine, cerebrospinal fluid (CSF), and the brain suggest the investigational treatment’s potential impact on this disease. Details can be found here.